Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J H Simon

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Neurology|August 17, 1999
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosisF Fazekas, F Barkhof, M Filippi, et al.
Neurology|May 10, 2006
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disabilityD K B Li, U Held, J Petkau, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 1, 1995
A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG)L D Jacobs, D L Cookfair, R A Rudick, et al.
Neurology|September 11, 2002
Benefit of interferon beta-1a on MSFC progression in secondary progressive MSJ A Cohen, G R Cutter, J S Fischer, et al.
AJNR. American Journal of Neuroradiology|November 14, 2015
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple SclerosisA Traboulsee, J H Simon, L Stone, et al.
Archives of Neurology|June 19, 2001
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trialJ A Cohen, G R Cutter, J S Fischer, et al.
Neurology|May 22, 1998
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)R A Rudick, N A Simonian, J A Alam, et al.
Neurology|July 17, 1999
A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)J H Simon, L D Jacobs, M K Campion, et al.
Neurology|July 26, 2000
A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research GroupJ H Simon, J Lull, L D Jacobs, et al.
Annals of Neurology|December 16, 2000
Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research GroupJ S Fischer, R L Priore, L D Jacobs, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Neurology|August 17, 1999
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosisF Fazekas, F Barkhof, M Filippi, et al.
Neurology|May 10, 2006
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disabilityD K B Li, U Held, J Petkau, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 1, 1995
A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG)L D Jacobs, D L Cookfair, R A Rudick, et al.
Neurology|September 11, 2002
Benefit of interferon beta-1a on MSFC progression in secondary progressive MSJ A Cohen, G R Cutter, J S Fischer, et al.
AJNR. American Journal of Neuroradiology|November 14, 2015
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple SclerosisA Traboulsee, J H Simon, L Stone, et al.
Archives of Neurology|June 19, 2001
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trialJ A Cohen, G R Cutter, J S Fischer, et al.
Neurology|May 22, 1998
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)R A Rudick, N A Simonian, J A Alam, et al.
Neurology|July 17, 1999
A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)J H Simon, L D Jacobs, M K Campion, et al.
Neurology|July 26, 2000
A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research GroupJ H Simon, J Lull, L D Jacobs, et al.
Annals of Neurology|December 16, 2000
Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research GroupJ S Fischer, R L Priore, L D Jacobs, et al.
Pageof 14